Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Stevens-Johnson syndrome and abuse of anabolic steroids

  • Cocca, Serena (Department of ENT, General Hospital of Siena, University of Siena) ;
  • Viviano, Massimo (Department of Dentistry, General Hospital of Siena, University of Siena)
  • Received : 2016.07.31
  • Accepted : 2016.09.01
  • Published : 2017.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Stevens-Johnson syndrome (SJS) is characterized by mucocutaneous tenderness and typical hemorrhagic erosions, erythema and epidermal detachment presenting as blisters and areas of denuded skin. SJS is often observed after drug use as well as after bacterial or viral infections. Several drugs are at high risk of inducing SJS, but there are no cases in the English literature regarding anabolic steroid use triggering SJS. In our paper, we describe a case in which use of anabolic androgenic steroids (AAS) was associated with SJS. The patient participated in competitive body-building and regularly took variable doses of AAS. Initial symptoms (headache, weakness, pharyngodynia, and fever) were ignored. After a week he presented to the Emergency Department with a burning sensation on the mouth, lips, and eyes. Painful, erythematous, maculopapular, and vesicular lesions appeared all over the body, including on the genitals. During hospitalization, he also developed a cardiac complication. The patient had not taken any drugs except AAS.

Keywords

References

  1. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia; report of two cases in children. Am J Dis Child 1922;24:526-33. https://doi.org/10.1001/archpedi.1922.04120120077005
  2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-61. https://doi.org/10.1111/j.1365-2133.1956.tb12766.x
  3. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997;24:726-9. https://doi.org/10.1111/j.1346-8138.1997.tb02524.x
  4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6. https://doi.org/10.1001/archderm.1993.01680220104023
  5. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007;62:527-31. https://doi.org/10.1111/j.1398-9995.2006.01295.x
  6. Sargenti Neto S, de Paulo LF, Rosa RR, Durighetto AF. Stevens-Johnson syndrome: an oral viewpoint. Int J Pediatr Otorhinolaryngol 2013;77:284-6. https://doi.org/10.1016/j.ijporl.2012.10.019
  7. Sawant SP, Amin AS. Mycoplasma pneumoniae associated Stevens-Johnson syndrome in an eight-year-old girl. Pediatr Infect Dis J 2013;5:13-5.
  8. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 2010;95:1533-43. https://doi.org/10.1210/jc.2009-1579
  9. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008;154:502-21. https://doi.org/10.1038/bjp.2008.165
  10. Fineschi V. Anabolic androgenic steroids (AAS) as doping agents: chemical structures, metabolism, cellular responses, physiological and pathological effects. Mini Rev Med Chem 2011;11:359-61. https://doi.org/10.2174/138955711795445871
  11. Mokhtari F, Nikyar Z, Naeini BA, Esfahani AA, Rahmani S. Adverse cutaneous drug reactions: eight year assessment in hospitalized patients. J Res Med Sci 2014;19:720-5.
  12. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486. https://doi.org/10.1038/428486a
  13. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-9. https://doi.org/10.1073/pnas.0409500102
  14. Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med 2007;121:48-53.
  15. Scully C, Bagan J. Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg 2008;46:90-5. https://doi.org/10.1016/j.bjoms.2007.07.202
  16. van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol 2010;57:117-23. https://doi.org/10.1016/j.yrtph.2010.02.001
  17. Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V. Side effects of AAS abuse: an overview. Mini Rev Med Chem 2011;11:374-89. https://doi.org/10.2174/138955711795445925
  18. Di Paolo M, Agozzino M, Toni C, Luciani AB, Molendini L, Scaglione M, et al. Sudden anabolic steroid abuse-related death in athletes. Int J Cardiol 2007;114:114-7. https://doi.org/10.1016/j.ijcard.2005.11.033